Medical marijuana is legal in the State of Florida. In 2019, a bill was passed to amend certain terms used for the use of medical marijuana also called MM. Bill 182 proposed several changes and one of them was the use of MM for pediatric patients. First of all, it states that it is illegal to prescribe MM in a form of smoking to patients under the age of 18 that do not have a terminal illness. If the patient does have a terminal condition, then the patient can be prescribed the smoking form of MM, but it must be approved by a second doctor that is a board certified pediatrician (The Florida Senate, n.d.). Consent must also be obtained from the patient’s parent or legal guardian (The Florida Senate, n.d.).
MM is usually prescribed in oncology patients to help with the side effects of nausea and vomiting from chemotherapy and to help control pain. There is not a lot of research done pertaining to the evidence base practice of smoking MM in pediatric patients. “There are no data indicating the rational and optimal way of MM dosing and administration, nor have dose finding studies been published in pediatric oncology patients so far” (Ofir et al., 2019). In this article, Studies were performed on oncology pediatric patients using cannabis in the form of oil, smoking, capsules, and vaporization (Ofir et al., 2019). Reasons for prescribing MM were nausea, vomiting, depression, sleeping problems, decreased appetite, pain, and weight loss (Ofir et al., 2019). The patients that used cannabis in the form of smoking were the ones that had the most side effects which included a “burning in their throat and anxiety attacks” (Ofir et al. 2019). On the other hand, some patients had positive feedback smoking MM and where able to sleep better, gain weight, and had decreased depression (Ofir et al., 2019).
It is hard to say whether MM helps the pediatric population because not much research has been conducted. One thing is for sure, no child should have to suffer the devastating effects of cancer and cancer treatment. At this point there is not enough evidence base to support the use of MM in the form of smoking in pediatric patients. There are studies that have been performed with people that smoke recreational marijuana. Long-term side effects of using recreational cannabis are measured by the levels of TCH to CBD (Aran & Cayam-Rand, 2020). According to Aran and Cayam-Rand:
Several large studies have demonstrated that the main risks of decreased motivation, addiction, mild cognitive decline, and schizophrenia are directly related to the THC and CBD concentrations in the strain used, i.e., the higher the ratio of THC to CBD, the greater the risk. The risk is also elevated among those with younger onset of use (<18 years) and in the presence of other risk factors, such as a family history of schizophrenia and concomitant use of alcohol and tobacco (2020).
References
Aran, A., & Cayam-Rand, D. (2020). Medical Cannabis in Children. Rambam Maimonides medical journal, 11(1), e0003. https://doi.org/10.5041/RMMJ.10386
Ofir, R., Bar-Sela, G., Weyl Ben-Arush, M., & Postovsky, S. (2019). Medical marijuana use for pediatric oncology patients: single institution experience. Pediatric Hematology and Oncology, 36(5), 255–266. https://doi.org/10.1080/08880018.2019.1630537
The Florida Senate. 2019 Bill Summaries – The Florida Senate. (n.d.). Retrieved January 13, 2022, from https://flsenate.gov/Committees/BillSummaries/2019/html/2067